Background & Aims
Direct-acting anti-viral agents suppress hepatitis B virus (HBV) load but must be given
lifelong. Stimulation of the innate immune system could increase its ability to control the virus
and have long lasting effects, after a finite regimen. We investigated the effects of immune
activation with GS-9620—a potent and selective orally active small molecule agonist of
Toll-Like Receptor (TLR)7—in chimpanzees with chronic HBV infection.
Methods
GS-9620 was administered to chimpanzees every other day (3 times each week) for 4 weeks
at 1 mg/kg and, after a 1 week rest, for 4 weeks at 2 mg/kg. We measured viral load in plasma and
liver samples, the pharmacokinetics of GS-9620, and the following pharmacodynamics parameters:
interferon (IFN)-stimulated gene expression, cytokine and chemokine levels, lymphocyte and natural
killer cell activation, and viral antigen expression. Clinical pathology parameters were monitored
to determine the safety and tolerability of GS-9620.
Results
Short-term oral administration of GS-9620 provided long-term suppression of serum and
liver HBV DNA. The mean maximum reduction of viral DNA was 2.2 logs, which occurred within 1 week of
the end of GS-9620 administration; reductions of greater than 1 log persisted for months. Serum
levels of HB surface antigen and HB e antigen, and numbers of HBV antigen-positive hepatocytes, were
reduced as hepatocyte apoptosis increased. GS-9620 administration induced production of
IFN-α and other cytokines and chemokines, and activated ISGs, natural killer cells, and
lymphocyte subsets.
Conclusions
The small molecule GS-9620 activates TLR-7 signaling in immune cells of chimpanzees to
induce clearance of HBV-infected cells. This reagent might be developed for treatment of patients
with chronic HBV infection.
Background & Aims
New therapies for chronic hepatitis B (CHB) are urgently needed since current treatments rarely lead to cure. We evaluated whether the oral small molecule toll-like receptor (TLR7) agonist GS-9620 could induce durable anti-viral efficacy in woodchucks chronically infected with woodchuck hepatitis virus (WHV), a hepadnavirus closely related to human hepatitis B virus (HBV).
Methods
After evaluating the pharmacokinetics, pharmacodynamics and tolerability of oral GS-9620 in uninfected woodchucks, adult woodchucks chronically infected with WHV (n=7 per group) were dosed with GS-9620 or placebo for 4 or 8 weeks with different treatment schedules.
Results
GS-9620 treatment induced rapid, marked and sustained reduction in serum viral DNA (mean maximal 6.2 log10 reduction), and hepatic WHV DNA replicative intermediates, WHV cccDNA and WHV RNA, as well as loss of detectable serum WHV surface antigen (WHsAg). GS-9620 treatment also induced a sustained antibody response against WHsAg in a subset of animals. Strikingly, treatment reduced the incidence of hepatocellular carcinoma (HCC) from 71% in the placebo group to 8% in GS-9620-treated woodchucks with sustained viral load reduction. GS-9620 treatment was associated with reversible increases in serum liver enzymes and thrombocytopenia, and induced intrahepatic CD8+ T cell, NK cell, B cell and interferon (IFN) response transcriptional signatures.
Conclusions
The data demonstrate that short duration, finite treatment with the oral TLR7 agonist GS-9620 can induce a sustained antiviral response in the woodchuck model of CHB, and support investigation of this compound as a therapeutic approach to attain a functional cure in CHB patients.
Conventional antibody-drug conjugates (ADCs) are heterogeneous mixtures of chemically distinct molecules that vary in both drugs/antibody (DAR) and conjugation sites. Suboptimal properties of heterogeneous ADCs have led to new site-specific conjugation methods for improving ADC homogeneity. Most site-specific methods require extensive antibody engineering to identify optimal conjugation sites and introduce unique functional groups for conjugation with appropriately modified linkers. Alternative nonrecombinant methods have emerged in which bifunctional linkers are utilized to cross-link antibody interchain cysteines and afford ADCs containing four drugs/antibody. Although these methods have been shown to improve ADC homogeneity and stability in vitro, their effect on the pharmacological properties of ADCs in vivo is unknown. In order to determine the relative impact of interchain cysteine cross-linking on the therapeutic window and other properties of ADCs in vivo, we synthesized a derivative of the known ADC payload, MC-MMAF, that contains a bifunctional dibromomaleimide (DBM) linker instead of a conventional maleimide (MC) linker. The DBM-MMAF derivative was conjugated to trastuzumab and a novel anti-CD98 antibody to afford ADCs containing predominantly four drugs/antibody. The pharmacological properties of the resulting cross-linked ADCs were compared with analogous heterogeneous ADCs derived from conventional linkers. The results demonstrate that DBM linkers can be applied directly to native antibodies, without antibody engineering, to yield highly homogeneous ADCs via cysteine cross-linking. The resulting ADCs demonstrate improved pharmacokinetics, superior efficacy, and reduced toxicity in vivo compared to analogous conventional heterogeneous ADCs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.